Bhaskar Vyas
This is a research innovation that aims to provide an additional therapeutic tool. It will open up a vast panorama of regenerative medicine by application of adipose derived Mesenchymal stem cells (ADMSCs). ADMSCs are selected on account of the large amount available for lipoaspiration and a larger percentage (30%) of Mesenchymal stem cells (MSCs) obtainable there from. The applications in clinical practice extend across mesoderm, endoderm, and ectoderm layers.
There are three products that can be derived from the lipoaspirate.
They are (1) stromal vascular fraction (SVF), (2) islet cell aggregates (ICAs) translated from ADMSCs, (3) and ADMSCs with ~95% purity. They are deployed to illustrate the safety and efficacy in clinical trials for (1) mesoderm translation as in osteoarthritis knee, (2) endoderm translation to insulin-producing cells as applicable to diabetes, and (3) ectodermal translation as applicable in retinal blindness as well as in nonhealing indolent ulcers on the skin.
All three products are found safe with no adverse side effects. Proof of concept studies along with initial clinical trials for osteoarthritis, diabetes types I and II, retinal blindness, and nonhealing ulcer of any aetiology have been conducted.
Autologous SVF and ADMSCs are in futuristic domain for conducting clinical trials across all the three germinal layers.
Share this article
Journal of Oncology Translational Research received 93 citations as per Google Scholar report
